Product Information
RUFINAMIDE 40 MG/ML SUSPENSION is a generic product labeled by Aurobindo Pharma Limited, priced at $0.2034 per ML under NDC 59651056360. Its NADAC has been published 178 times since May 10, 2023.
FDA first approved this application on Oct 26, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40 mg/mL
Manufacturer
Aurobindo Pharma LimitedNDC
59651056360
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RUFINAMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA216549FDA Approved
10/26/2022
TE Code
AB
On Market Since
10/26/2022
Price Statistics
The NADAC for RUFINAMIDE 40 MG/ML SUSPENSION has been published 178 times since May 10, 2023, and over the history we have for it it has declined 79.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2034 per ML |
|---|---|
| All-time high | $1.4122 (Aug 16, 2023) |
| All-time low | $0.2021 (Jul 22, 2026) |
| 52-week high | $0.3679 |
| 52-week low | $0.2021 |
| Median price | $0.3679 |
| Average price | $0.4793 |
| Largest weekly change | -53.3% (Sep 20, 2023) |
| Weeks tracked | 178 |
| Tracking since | May 10, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the RUFINAMIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
RUFINAMIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RUFINAMIDE 40 MG/ML SUSPENSION?
The current National Average Drug Acquisition Cost (NADAC) for RUFINAMIDE 40 MG/ML SUSPENSION, manufactured by Aurobindo Pharma Limited, is $0.2034 per ML (NDC 59651056360), effective Sep 30, 2026.
How has the price of RUFINAMIDE 40 MG/ML SUSPENSION changed over time?
Over the history we have for it, the NADAC for RUFINAMIDE 40 MG/ML SUSPENSION has declined 79.6%. It has been tracked across 178 weekly CMS publications since May 10, 2023.
What are the highest and lowest recorded NADAC prices for RUFINAMIDE 40 MG/ML SUSPENSION?
Since May 10, 2023, the NADAC for RUFINAMIDE 40 MG/ML SUSPENSION has ranged from a low of $0.2021 (Jul 22, 2026) to a high of $1.4122 (Aug 16, 2023), with a median of $0.3679 per ML.
Are there cheaper alternatives to RUFINAMIDE 40 MG/ML SUSPENSION?
No other NADAC-published product currently shares the active ingredient and strength of RUFINAMIDE 40 MG/ML SUSPENSION in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RUFINAMIDE 40 MG/ML SUSPENSION?
RUFINAMIDE 40 MG/ML SUSPENSION (NDC 59651056360) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.